Results 221 to 230 of about 1,583,153 (391)

Quality management by state Medicaid agencies converting to managed care: plans and current practice.

open access: yesJournal of the American Medical Association (JAMA), 1998
B. Landon, C. Tobias, A. Epstein
semanticscholar   +1 more source

Impact of Asymptomatic Intracranial Hemorrhage on Outcome After Endovascular Stroke Treatment

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Endovascular treatment (EVT) achieves high rates of recanalization in acute large‐vessel occlusion (LVO) stroke, but functional recovery remains heterogeneous. While symptomatic intracranial hemorrhage (sICH) has been well studied, the prognostic impact of asymptomatic intracranial hemorrhage (aICH) after EVT is less certain ...
Shihai Yang   +22 more
wiley   +1 more source

Harm reduction services and interventions for People Who Use Drugs (PWUD) in Latin America and the Caribbean (LAC) between 2013-2024: A scoping review protocol. [PDF]

open access: yesPLoS One
Bórquez I   +8 more
europepmc   +1 more source

Managed Care after Acute Myocardial Infarction (MC-AMI) improves prognosis in AMI survivors with pre-existing heart failure: A propensity score matching analysis of Polish nationwide program of comprehensive post-MI care

open access: diamond, 2022
Mariusz Gąsior   +16 more
openalex   +2 more sources

Trends in Dermatopolymyositis Mortality, 1999–2022: A Nationwide Population‐Based Study, United States

open access: yesArthritis Care &Research, EarlyView.
We report the national burden of dermatopolymyositis mortality over the past quarter century using the US national vital statistics data. Age‐standardized mortality rates for dermatopolymyositis decreased at an annual rate of 3.8% each year, which was higher than the annual percent decrease for deaths from all other causes.
Elizabeth Matz, Ram R. Singh
wiley   +1 more source

Commercial managed care plans leaving the Medicaid Managed Care Program in New York State: Impact on quality and access [PDF]

open access: bronze, 2000
Patrick J. Roohan   +4 more
openalex   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy